Cigna Group (CI) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-14

Key Insights

CEO David Cordani executed a substantial net sell of approximately 189,000 shares on May 12-13, 2026, with sale prices ranging from $286-$298 per share, generating roughly $55 million in proceeds after acquiring shares through option exercises.
The sales were conducted under a Rule 10b5-1 trading plan adopted on February 6, 2026, indicating pre-planned, non-discretionary selling that reduces concerns about negative company outlook signaling.
Cordani acquired 189,114 shares through the exercise of employee stock options at prices of $149.14 and $197.35, then immediately sold 189,048 shares at significantly higher prices, executing a classic cashless exercise and diversification strategy.
Following all transactions, Cordani maintains direct ownership of 34,337 shares plus indirect beneficial ownership through a GRAT (440,798 shares), Trust (157,935 shares), and 401(k) (1,803 shares), demonstrating continued significant equity stake despite the reduction.

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-24

Director Kathleen M. Mazzarella acquired 782 shares of Cigna Group common stock on April 22, 2026, at $0 consideration, indicating a stock grant or award rather than an open market purchase.
The acquisition increased Mazzarella's total beneficial ownership to 6,891 shares held directly, suggesting accumulated equity compensation over her tenure as a board member.
The filing shows no derivative securities activity, and the transaction was made pursuant to a pre-arranged plan (Rule 10b5-1 compliance indicated), reflecting standard director compensation practices rather than discretionary trading.
No significant insider selling pressure is evident from this transaction; the acquisition of relatively modest share quantities aligns with routine director equity compensation patterns at large-cap healthcare companies.

Filed: 2026-04-24

Director Eric J. Foss acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a grant or award rather than an open market purchase, likely part of director compensation.
Following this transaction, Foss's direct beneficial ownership increased to 36,696 shares, demonstrating continued significant personal investment in the company aligned with shareholder interests.
The filing was executed through a power of attorney by Tyler Gratton and filed on 04/24/2026, following standard administrative procedures for insider transactions by board members.

Filed: 2026-04-24

Director Mark B. McClellan acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a dividend reinvestment or stock award rather than a market purchase.
McClellan's total beneficial ownership increased to 6,891 shares following this transaction, representing a modest accumulation that suggests continued confidence in the company's direction.
The transaction was executed through a Power of Attorney by Tyler Gratton and filed within two business days, demonstrating proper insider trading compliance procedures.

Filed: 2026-04-24

Director Neesha Hathi acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a grant or equity compensation award rather than an open market purchase.
The acquisition brings the director's total beneficial ownership to 4,151 shares held directly, representing a modest equity stake that aligns her interests with shareholders.
The $0 transaction price and use of a power of attorney suggests this was part of a standard director compensation or equity plan execution rather than a discretionary buy signal.

Filed: 2026-04-24

Director Donna F. Zarcone acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a stock award or grant rather than open market purchase, bringing her total beneficial ownership to 27,517 shares.
The filing notes that Zarcone's economic interest includes additional hypothetical shares tied to Cigna stock value that are settled in cash upon separation, suggesting deferred compensation arrangements beyond the reported direct holdings.
As a Director, this transaction represents routine equity compensation issuance typical for board members, with no indication of insider selling or loss of confidence in the company's valuation.

Filed: 2026-04-24

Director George Kurian acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 per share, indicating a stock grant or equity award rather than an open market purchase, bringing his total beneficial ownership to 4,560 shares.
The filing reveals Kurian holds additional economic interests in hypothetical shares tied to Cigna stock value that are settled in cash upon separation, suggesting significant deferred compensation arrangements beyond direct share ownership.
As a Director (not an Officer), Kurian's equity stake increase demonstrates board-level alignment with shareholder interests through compensation structure tied to company performance.

Filed: 2026-04-24

Director Ross Kimberly A. acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a stock grant or dividend reinvestment rather than an open market purchase.
The reporting person is a Director at Cigna, and following this transaction, holds 5,294 shares directly, suggesting meaningful but not substantial personal equity stake in the company.
The transaction was processed through a Power of Attorney held by Tyler Gratton and filed on 04/24/2026, representing routine insider activity without evidence of significant conviction buying or selling pressure.

Filed: 2026-04-24

Director Michael J Hennigan acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a stock award or grant rather than open market purchase, bringing his total beneficial ownership to 1,350 shares.
The transaction appears to be equity compensation (likely restricted stock or performance shares) given the zero dollar price, which is typical for director or executive compensation arrangements rather than discretionary buying.
As a Director holding only 1,350 shares post-transaction, Hennigan's ownership stake is relatively modest, suggesting limited personal capital deployed in the company and potentially less skin-in-the-game than institutional expectations.

Filed: 2026-04-24

Director Philip Ozuah acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating a stock award or grant rather than open market purchase, which is typical for director compensation.
Post-transaction beneficial ownership stands at 2,583 shares held directly by Ozuah, reflecting his ongoing stake in the company as a board member.
The transaction was executed through a Power of Attorney by Tyler Gratton and filed on 04/24/2026, suggesting routine insider administrative activity rather than discretionary trading decisions.
No derivative securities (options, warrants) are involved in this filing, indicating this is purely an equity compensation event with no hedging or speculative positioning.

Filed: 2026-04-24

Director Eric C. Wiseman acquired 782 shares of Cigna Group common stock on 04/22/2026 at $0 price, indicating this was likely a grant or dividend reinvestment rather than open market purchase
Following the transaction, Wiseman's beneficial ownership increased to 23,940 shares, demonstrating sustained significant equity stake in the company as a board member
The filing notes that Wiseman's economic interest includes additional hypothetical shares tied to Cigna stock value that are settled in cash, suggesting deferred compensation arrangements beyond the disclosed direct holdings
The use of a power of attorney (Tyler Gratton) for filing suggests routine administrative processing of director equity compensation rather than discretionary trading activity

Other reports for Cigna Group

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.